Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
Table 1
Clinicopathologic correlation of ERα.
Sl no.
Attribute
ERα positive (n = 32)
ERα negative (n = 232)
valuea overall
valuea PTC
valuea FTC
valuea PDTC
1.
Age in years (mean ± SD)
49.2 ± 15.1
45.8 + 15.5
0.24
0.654
0.347
0.199
2.
Gender (M : F)
11 : 31
79 : 153
1.00
0.043
0.229
0.088
3.
Presence of PDAb, n (%)
11 (40.7)
79 (39.3)
0.33
0.970
0.590
—
4.
Tumor size in cm (mean ± SD)
5.2 ± 3.1
4.6 ± 2.8
1.00
0.210
1.000
0.862
5.
Multicentricity, n (%)
8 (25.0)
62 (27.4)
0.83
0.524
1.000
0.029
6.
Extrathyroidal extension, n (%)
7 (21.9)
58 (25.4)
0.82
0.451
0.669
1.000
7.
Lymph node metastases, n (%)
12 (37.5)
90 (39.0)
1.00
0.739
1.000
0.630
8.
Distant metastases, n (%)
15 (48.4)
68 (29.4)
0.04
1.000
0.062
1.000
9.
Recurrence, n (%)
2 (6.2)
23 (9.9)
1.00
1.000
1.000
1.000
10.
Mean survival in months (n ± SE)
114 ± 11
191 ± 8
0.52
0.405
0.743
0.158
aAll values obtained on univariate analysis. bPDA, poorly differentiated areas. Significant positive correlation of ERα expression and occurrence of PTCs in males. Significant positive correlation of ERα expression and multicentric PDTC. Significant positive correlation of ERα expression and incidence of distant metastases.
